US 11,771,835 B2
Therapy assist information and/or tracking device and related methods and systems
John Sjolund, Los Altos, CA (US); Ambika Srinath, San Francisco, CA (US); Andrew Bochenko, Redwood City, CA (US); George Crothall, Oceanside, CA (US); Bryan Mazlish, Palo Alto, CA (US); Lane Desborough, Thousand Oaks, CA (US); Jennifer Martin Block, Menlo Park, CA (US); Sarah Matarese, San Jose, CA (US); and Linda Mackowiak, Cazenovia, NY (US)
Assigned to Bigfoot Biomedical, Inc., Milpitas, CA (US)
Filed by Bigfoot Biomedical, Inc., Milpitas, CA (US)
Filed on Jun. 7, 2021, as Appl. No. 17/303,748.
Application 17/303,748 is a continuation of application No. 16/218,026, filed on Dec. 12, 2018, granted, now 11,027,073.
Claims priority of provisional application 62/597,868, filed on Dec. 12, 2017.
Prior Publication US 2021/0290853 A1, Sep. 23, 2021
Int. Cl. A61B 5/00 (2006.01); A61M 5/315 (2006.01); G16H 20/17 (2018.01); A61B 5/145 (2006.01); A61M 5/20 (2006.01); G16H 50/20 (2018.01); G16H 50/30 (2018.01); G16H 40/63 (2018.01); G16H 20/60 (2018.01); A61M 5/168 (2006.01); G16H 40/67 (2018.01); G16H 20/13 (2018.01); A61K 38/28 (2006.01); A61M 5/32 (2006.01); A61M 5/00 (2006.01); A61M 5/142 (2006.01); A61M 5/24 (2006.01); A61M 5/31 (2006.01)
CPC A61M 5/31546 (2013.01) [A61B 5/0004 (2013.01); A61B 5/14532 (2013.01); A61B 5/4836 (2013.01); A61B 5/4839 (2013.01); A61B 5/7405 (2013.01); A61B 5/746 (2013.01); A61B 5/7435 (2013.01); A61B 5/7455 (2013.01); A61K 38/28 (2013.01); A61M 5/003 (2013.01); A61M 5/168 (2013.01); A61M 5/20 (2013.01); A61M 5/31525 (2013.01); A61M 5/3202 (2013.01); G16H 20/13 (2018.01); G16H 20/17 (2018.01); G16H 20/60 (2018.01); G16H 40/63 (2018.01); G16H 40/67 (2018.01); G16H 50/20 (2018.01); G16H 50/30 (2018.01); A61B 5/14546 (2013.01); A61B 5/681 (2013.01); A61M 5/24 (2013.01); A61M 2005/14208 (2013.01); A61M 2005/2006 (2013.01); A61M 2005/3125 (2013.01); A61M 2205/18 (2013.01); A61M 2205/3306 (2013.01); A61M 2205/3561 (2013.01); A61M 2205/3584 (2013.01); A61M 2205/502 (2013.01); A61M 2205/505 (2013.01); A61M 2205/581 (2013.01); A61M 2205/582 (2013.01); A61M 2205/583 (2013.01); A61M 2209/06 (2013.01); A61M 2230/201 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A pen cap for an insulin pen comprising:
at least one user interface to display at least one of therapy relevant information, therapy recommendations, or a time of the at least one of a capping or decapping of the pen cap;
a controller comprising:
at least one processor; and
at least one non-transitory computer-readable storage medium storing instructions thereon that, when executed by the at least one processor, cause the controller to:
detect at least one of a capping or decapping of the pen cap from an insulin pen; and
responsive to the pen cap being capped on the insulin pen for a threshold period of time, cause the at least one user interface to display a recommended correction dose of insulin based at least partially on an insulin sensitivity factor and a target glucose value.